Research in Motion Ltd. (NASDAQ:RIMM) was upgraded twice this week. On Monday, RBC upgraded RIMM to Outperform from Sector Perform with a $180 target. Following Tuesday's selloff, ThinkEquity upgraded RIMM yesterday to Buy from Accumulate with a $165 target, believing the selloff created a buying opportunity.
RIM said on Tuesday that it expects to report the results of its internal stock-option review Monday next week. It's going to miss the Friday deadline, but at least the end is in sight and investors can sigh in relief. RIM said in the past it would likely need to restate some financials following the review, but these are generally believed to be insignificant in the magnitude of no more than $45 million.
Meanwhile, the BlackBerry Pearl continues to have strong sales and the new 8800 is also promising. The downside, of course, is the upcoming Apple Inc. (NASDAQ:AAPL) iPhone, which is expected to be a main competitor.
RIMM shares continue to show resilience and are up 10% year-to-date despite the significant drop after the iPhone was announced. I, for one, would like to wait and see who buys the iPhone before I'd doom RIM. It's quite possible the iPhone will be more popular with the younger crowd, while RIM will continue to be the business crowd favorite.
I don't know if I would call RIMM a bargain stock with its P/E of 57 and its forward P/E of 30, but I'd still consider it now. RIMM is up 50c today or 0.36% to $141.11, still off its 52-week high of $147.05, but definitely not bad on a general down day.
Last updated: February 13, 2012: 07:33 AM
Hot Stocks
DailyFinance Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
Benzinga Headlines
- Seven Japanese Stocks Up More Than 10% Year to Date
- Does the 2012 Election Really Matter for the Economy?
- Michigan Consumer Sentiment Index Drops
- Don't Bank on Barclays
- GSV Capital Punished for Expanding Facebook Investment
TheFlyOnTheWall.com Headlines
- Symantec management to meet with UBS
- Boeing: Dreamliner glitch won't slow production, CNBC reports
- NetApp downgraded to Hold from Buy at ThinkEquity
- Pricing for ultrabooks won't hit 'sweet spot' until 2013, DigiTimes says
- EQT Corporation subsidiary files registration statement
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger


Reader Comments (Page 1 of 1)
3-01-2007 @ 4:47PM
bbbrooks003 said...
However, they also compete directly woth Motorola. The Market Cap of both Companies is converging, I see a downside because I don't think it's a Motorola. Do you?